146 14. Marambaud P, Shioi J, Serban G, Georgakopoulos G, Sarner S, Nagy V et al. A presenilin-1/g-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002;21:1948 – 1956. 15. Dwivedi A, Slater S, George S. MMP-9 and -12 cause N-cadherin shedding and thereby b-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 2008;81:178 – 186. 16. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metallo- proteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocepha- lic arteries. Proc Natl Acad Sci USA 2005;102:15575 – 15580. 17. Koutsouki E, Aguilera-Garcia CM, Sala-Newby GB, Newby AC, George SJ. Cell-cell contact by cadherins provides an essential survival signal to migrating smooth muscle cells. Eur Heart J 2003;24:1838. 18. Koolwijk P, Sidenius N, Peters E, Sier CFM, Hanemaaijer R, Blasi F et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: impli- cation for angiogenesis in ﬁbrin matrices. Blood 2001;97:3123 – 3131. 19. Zhong J, Gencay MMC, Bubendorf L, Burgess JK, Parson H, Robinson BWS et al. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell mipration: A comparison between mesothelioma and mesothelial cells. Journal Of Cellular Physiology 2006;207:540 – 552. 20. Dublanchet AC, Ducrot P, Andrianjara C, O’Gara M, Morales R, Compere D et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Medic Chem Letts 2005;15:3787 – 3790. 21. Morales R, Perrier S, Florent JM, Beltra J, Dufour S, De Mendez I et al. Crystal struc- tures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J Mol Biol 2004;341:1063 – 1076. 22. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated ﬁbroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res 2001;38:492 – 501. 23. George SJ, Johnson JL, Smith MA, Jackson CL. Transforming growth factor-b is acti- vated by plasmin and inhibits smooth muscle cell death in human saphenous vein. J Vas Res 2005;42:247 – 254. 24. Irvine CD, George SJ, Shefﬁeld E, Johnson JL, Davies AH, Lamont PM. The association of PDGF recepetor expression, plaque morphology and histological features with symptoms in carotid atherosclerosis. Cardiovasc Surg 2000;8:121 – 129. 25. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overex- pression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296 – 304. 26. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006;113:2435 – 2444. 27. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E et al. ADAM10 med- iates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and b-catenin translocation. Proc Natl Acad Sci 2005;102:9182 – 9187. H. Williams et al. 28. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2000;114:111 – 118. 29. Rios-Doria J, Day KC, Keufer R, Rashid MG, Chinnaiyan AM, Rubin MA et al. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epi- thelial cells. J Biol Chem 2003;278:1372 – 1379. 30. Ryniers F, Stove C, Goethals M, Brackenier L, Noe V, Bracke M et al. Plasmin pro- duces an E-cadherin fragment that stimulated cancer cell invasion. Biol Chem 2002; 383:159 – 165. 31. Wu W-B, Huang T-F. Activation of MMP-2, cleavage of matrix proteins, and adherens junctions during a snake venom metalloproteinase-induced endothelial cell apoptosis. Exp Cell Res 2003;288:143. 32. Simian M, Molinolo A, Lanari C. Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Path 2006;168:270 – 279. 33. Covington MD, Bayless KJ, Burghardt RC, Davis GE, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. Am J Physiol Renal Physiol 2005;289:F280 – F288. 34. Davies G, Jiang W, Mason M. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001;7: 3289 – 3297. 35. Stephen NH, Frank M, Rebecca LA, Armand A, Xiaoying Z, Julian W et al. Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the clea- vage of cellular N-cadherin. Liver Int 2009;29:966 – 978. 36. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-speciﬁc regulation of matrix metalloproteinase-7 promoter activity is associated with coron- ary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001;21:1834 – 1839. 37. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Sharipo SD et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748 – 9753. 38. Park JH, Park SM, Park SH, Cho KH, Lee ST. Cleavage and functional loss of human apolipoprotein E by digestion of matrix metalloproteinase-14. Proteomics 2008;8: 2926 – 2935. 39. Kim SY, Park SM, Lee S-T. Apolipoprotein C-II is a novel substrate for matrix metal- loproteinases. Biochem Biophys Res Commun 2006;339:47. 40. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloprotei- nase matrilysin proteolytically generates active soluble Fas ligand and potentiates epi- thelial cell apoptosis. Curr Biol 1999;9:1441. 41. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004;94:68 – 76.